{"id":"W2071539936","doi":"10.1097/jto.0b013e3182773fce","title":"Symptom and Quality of Life Benefit of Afatinib in Advanced Non–Small-Cell Lung Cancer Patients Previously Treated with Erlotinib or Gefitinib: Results of a Randomized Phase IIb/III Trial (LUX-Lung 1)","year":2013,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Medicine; Afatinib; Lung cancer; Placebo; Internal medicine; Gefitinib; Erlotinib; Adverse effect; Quality of life (healthcare); Randomized controlled trial; Chest pain; Gastroenterology; Cancer; Pathology; Epidermal growth factor receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001225039,0.00024684,0.002644799,0.0003352309,0.00003232775,0.000007107508,0.0001196942,0.0001771764,0.0001075445],"category_scores_gemma":[0.0008524854,0.0001492226,0.0002405595,0.0003284842,0.0001893129,0.0001741625,0.0000328058,0.0002534593,2.573939e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002638459,"about_ca_system_score_gemma":0.001349943,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001470862,"about_ca_topic_score_gemma":0.000378804,"domain_scores_codex":[0.9959283,0.0004386234,0.002741538,0.0002452894,0.0003793726,0.0002668288],"domain_scores_gemma":[0.9929374,0.001197459,0.004200728,0.0002228753,0.001207015,0.0002344629],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9382192,0.004813289,0.03018918,0.0008515783,0.001310429,0.00002030766,0.004266256,0.0001459029,0.001930093,0.000005453517,0.0001262336,0.01812201],"study_design_scores_gemma":[0.9556687,0.01345652,0.02089867,0.001598536,0.003155379,0.00001558602,0.0008187799,0.0003620284,0.003808229,0.00001119412,0.00004416262,0.0001621645],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.993539,0.001240774,0.00004707128,0.0003093805,0.0001805775,0.003945069,0.0001088777,0.000006429278,0.0006228664],"genre_scores_gemma":[0.9958334,0.0006886799,0.0026675,0.00006925342,0.00009018686,0.0002022363,0.00003218137,0.00002614059,0.0003904423],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01795985,"threshold_uncertainty_score":0.608512,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02487591600355954,"score_gpt":0.4309749554100554,"score_spread":0.4060990394064959,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}